UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
MBRX holding history
Moleculin Biotech, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
MBRX overviewAll 13F holders of MBRXFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −3,409−100.0% | Sold out | Holders |
| Q1 2026 | 3,409 | $7.81K | <0.1% | −2,454−41.9% | Reduced | Holders |
| Q4 2025 | 5,863 | $19.4K | <0.1% | +5,704+3,596.7% | AddedConverted for a 1-for-25 split | Holders |
| Q3 2025 | 3,965 | $2.10K | <0.1% | −4,024−50.4% | Reduced | Holders |
| Q2 2025 | 7,989 | $2.41K | <0.1% | +7,989 | New | Holders |
| Q1 2025 | 0 | $0 | 0.0% | −8,939−100.0% | Sold out | Holders |
| Q4 2024 | 8,939 | $15.2K | <0.1% | +8,939 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −200−100.0% | Sold out | Holders |
| Q3 2023 | 200 | $85 | <0.1% | +200 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −11,243−100.0% | Sold out | Holders |
| Q4 2022 | 11,243 | $11.9K | <0.1% | +799+7.7% | Added | Holders |
| Q3 2022 | 10,444 | $11.0K | <0.1% | +8,791+531.8% | Added | Holders |
| Q2 2022 | 1,653 | $2.00K | <0.1% | +1,653 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −1,403−100.0% | Sold out | Holders |
| Q3 2021 | 1,403 | $4.00K | <0.1% | +332+31.0% | Added | Holders |
| Q2 2021 | 1,071 | $4.00K | <0.1% | +1,071 | New | Holders |